𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Focal nodular hyperplasia: Intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging

✍ Scribed by Daniele Marin; Riccardo Iannaccone; Andrea Laghi; Carlo Catalano; Takamichi Murakami; Masatoshi Hori; Tonsok Kim; Roberto Passariello


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
261 KB
Volume
25
Category
Article
ISSN
1053-1807

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Purpose

To intraindividually compare the enhancement pattern of focal nodular hyperplasia (FNH) after dynamic administration of two bolus‐injectable liver‐specific MR contrast agents, ferucarbotran and gadobenate dimeglumine.

Materials and Methods

A total of 19 patients with 24 FNHs underwent gadobenate dimeglumine‐ and ferucarbotran‐enhanced MRI during the hepatic arterial‐dominant phase (HAP; 25 seconds), the portal‐venous phase (PVP; 60 seconds), and the equilibrium phase (EP; 180 seconds). Hepatospecific phases were acquired on T1‐weighted images 120 minutes after gadobenate dimeglumine administration, and on T2‐weighted images 10 minutes after ferucarbotran administration. Lesion enhancement was independently analyzed by two observers. The kappa statistic was determined to evaluate the agreement between the enhancement patterns of the lesions.

Results

On gadobenate dimeglumine–enhanced MR images during HAP, PVP, and EP, FNHs were: hyperintense (24/20/13); isointense (0/4/11); and hypointense (0/0/0). On ferucarbotran‐enhanced MR images during HAP, PVP, and EP, FNHs were: hyperintense (2/0/0); isointense (16/9/14); and hypointense (6/15/10). Overall, poor agreement between both contrast agents was observed. During the hepatospecific phases, most (20/24; 83%) FNHs showed a typical enhancement pattern during the delayed hepatospecific phase.

Conclusion

The dynamic enhancement pattern of FNHs is significantly different between gadobenate dimeglumine– and ferucarbotran‐enhanced MRI. With respect to hepatospecific phase, the majority of FNHs showed a typical behavior on both contrast agents. J. Magn. Reson. Imaging 2007. © 2007 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Prospective comparison of image quality
✍ Marina Achenbach; Jens H. Figiel; Mykhaylo Burbelko; Johannes T. Heverhagen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

## Abstract ## Purpose To compare image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast‐enhanced (CE) magnetic resonance angiography (MRA) of the lower extremities interindividually. ## Materials and Methods The study was approved by our I